Skip to Content

Canopy Growth Corp CGC

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Canopy Makes Progress to Profitability in Q3, but Massive Rally Has Pushed Shares to Overvalued

Analyst Note

| Kristoffer Inton |

Operationally, Canopy Growth continued to make good progress towards profitability in the third quarter of fiscal 2021. Net revenue grew 23% over the prior year quarter to nearly CAD 153 million, with adjusted EBITDA losses narrowing 29% to CAD 68 million. The company remains in the middle of a major reorganization, as shown by a CAD 400 million impairment charge it recognized during the quarter.

Read Full Analysis

Company Profile

Business Description

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.

Contact
1 Hershey Drive
Smiths Falls, ON, K7A 0A8, Canada
T +1 855 558-9333
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Dec 31, 2020
Fiscal Year End Mar 31, 2021
Stock Type
Employees 4,434

Related